eGenesis raises $38m for CRISPR-powered xenotransplantation

Share

eGenesis raises $38m for CRISPR-powered xenotransplantationA Cambridge, MA.-based firm got a $38 million boost towards it goal of harvesting animal organs to give to humans in dire need of a transplant. eGenesis, a spin-out from Harvard University, hopes to improve the supply of organs for patients that are stuck on the transplant waiting list.

While the seemingly science-fiction field of xenotransplantation is far away from bringing products into the clinic, it has grown in recent years thanks to the development of biological modification techniques like CRISPR-Cas9.

Get the full story at our sister site, MassDevice.

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*